Literature DB >> 11337491

Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm.

Y Leng1, T N Chase, M C Bennett.   

Abstract

The close correspondence between the distribution of brain alpha-synuclein and that of muscarinic M1 and M3 receptors suggests a role for this protein in cholinergic transmission. We thus examined the effect of muscarinic stimulation on alpha-synuclein in SH-SY5Y, a human dopaminergic cell line that expresses this protein. Under basal conditions, alpha-synuclein was detected in all subcellular compartments isolated as follows: plasma membrane, cytoplasm, nucleus, and two vesicle fractions. The lipid fractions contained only a 45-kDa alpha-synuclein oligomer, whereas the cytoplasmic and nuclear fractions contained both the oligomer and the monomer. This finding suggests alpha-synuclein exists physiologically as a lipid-bound oligomer and a soluble monomer. Muscarinic stimulation by carbachol reduced the alpha-synuclein oligomer in plasma membrane over a 30-min period, with a concomitant increase of both the oligomer and the monomer in the cytoplasmic fraction. The oligomer was associated with a light vesicle fraction in cytoplasm that contains uncoated endocytotic vesicles. The carbachol-induced alteration of alpha-synuclein was blocked by atropine. Translocation of the alpha-synuclein oligomer in response to carbachol stimulation corresponds closely with the time course of ligand-stimulated muscarinic receptor endocytosis. The data suggest that the muscarine receptor stimulated release of the alpha-synuclein oligomer from plasma membrane, and its subsequent association with the endocytotic vesicle fraction may have a role in muscarine receptor endocytosis. We propose that its function may be a transient release of membrane-bound phospholipase D2 from alpha-synuclein inhibition, thus allowing this lipase to participate in muscarinic receptor endocytosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337491     DOI: 10.1074/jbc.M011121200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  A loss in cellular protein partners promotes α-synuclein aggregation in cells resulting from oxidative stress.

Authors:  Yuanjian Guo; Suzanne Scarlata
Journal:  Biochemistry       Date:  2013-05-21       Impact factor: 3.162

3.  Upregulation of α-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways.

Authors:  L N Saligan; C P Hsiao; D Wang; X M Wang; L St John; A Kaushal; D Citrin; J J Barb; P J Munson; R A Dionne
Journal:  Brain Behav Immun       Date:  2012-09-26       Impact factor: 7.217

4.  Autophagy enhancement is rendered ineffective in presence of α-synuclein in melanoma cells.

Authors:  Swapna Nandakumar; Bejoy Vijayan; Asha Kishore; Anoopkumar Thekkuveettil
Journal:  J Cell Commun Signal       Date:  2017-07-26       Impact factor: 5.782

Review 5.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 6.  Linking alpha-synuclein properties with oxidation: a hypothesis on a mechanism underling cellular aggregation.

Authors:  Suzanne Scarlata; Urszula Golebiewska
Journal:  J Bioenerg Biomembr       Date:  2014-01-29       Impact factor: 2.945

7.  Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux.

Authors:  Roberta Marongiu; Brian Spencer; Leslie Crews; Anthony Adame; Christina Patrick; Margarita Trejo; Bruno Dallapiccola; Enza Maria Valente; Eliezer Masliah
Journal:  J Neurochem       Date:  2009-01-24       Impact factor: 5.372

8.  Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein.

Authors:  Gaofeng Wang; Joelle M van der Walt; Gregory Mayhew; Yi-Ju Li; Stephan Züchner; William K Scott; Eden R Martin; Jeffery M Vance
Journal:  Am J Hum Genet       Date:  2008-01-31       Impact factor: 11.025

Review 9.  Alpha-synuclein biology in Lewy body diseases.

Authors:  Woojin Scott Kim; Katarina Kågedal; Glenda M Halliday
Journal:  Alzheimers Res Ther       Date:  2014-10-27       Impact factor: 6.982

Review 10.  Mammalian phospholipase D: Function, and therapeutics.

Authors:  M I McDermott; Y Wang; M J O Wakelam; V A Bankaitis
Journal:  Prog Lipid Res       Date:  2019-12-09       Impact factor: 16.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.